Federal Register #FDA-2023-D-1987

FDA Final Guidance on Clinical Investigations of Psychedelic Drugs

The Food and Drug Administration (FDA), part of the Department of Health and Human Services, has released a final guidance document for industry regarding clinical investigations of psychedelic drugs. - Government Buyer: - Department of Health and Human Services - Food and Drug Administration (FDA) - Purpose: - Provides regulatory guidance for sponsors developing psychedelic drugs for medical conditions, including psychiatric and substance use disorders - Key Content: - Outlines considerations for clinical trial design, data collection, and patient monitoring - Addresses unique challenges in researching psychedelic compounds - Notable Details: - No procurement of products or services is involved - No OEMs, vendors, or part numbers are specified - Guidance is intended to assist industry sponsors in navigating regulatory requirements for psychedelic drug development

Description

The Food and Drug Administration (FDA) has announced the availability of a final guidance for industry titled "Psychedelic Drugs: Considerations for Clinical Investigations." This guidance addresses the therapeutic potential of psychedelic drugs and provides general considerations for sponsors developing these drugs for medical conditions such as psychiatric disorders and substance use disorders. It discusses recommendations for clinical investigations, including study design, data collection, and patient monitoring. The guidance finalizes a draft issued on June 26, 2023, and aims to assist sponsors in navigating the unique challenges of clinical trials involving psychedelic compounds.

View original listing